{
    "clinical_study": {
        "@rank": "117686", 
        "arm_group": [
            {
                "arm_group_label": "LEO 90100", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Petrolatum ointment", 
                "arm_group_type": "Other"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the skin irritation potential and sensitisation\n      potential of LEO 90100 and the vehicle after repeated applications on the skin of healthy\n      subjects."
        }, 
        "brief_title": "Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Psoriasis Vulgaris", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Following verbal and written information about the trial, subject must provide\n             signed and dated informed consent before any study related activities are carried\n             out.\n\n          -  2. Healthy male or female subjects, 18 to 65 years of age inclusive at screening.\n\n        Exclusion Criteria:\n\n          -  1. Female subjects who are pregnant, of childbearing potential and who wish to become\n             pregnant during the study, or who are breast feeding\n\n          -  2. Subjects with any systemic or cutaneous disorder that might interfere with the\n             evaluation of the test site reactions (e.g. atopic dermatitis, contact eczema,\n             psoriasis) 3. Subjects with scars, moles or other abnormal pigmentation of the skin\n             or skin type that could, in any way, confound interpretation of the study results\n             (skin type V and VI on the Fitzpatrick scale)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "224", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01935869", 
            "org_study_id": "LP0053-66"
        }, 
        "intervention": [
            {
                "arm_group_label": "LEO 90100", 
                "intervention_name": "LEO 90100", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "intervention_name": "Vehicle", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Petrolatum ointment", 
                "intervention_name": "Petrolatum ointment", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Petrolatum"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nice Cedex 3", 
                    "country": "France", 
                    "zip": "06202"
                }, 
                "name": "CPCAD, Centre de Pharmacologie Clinique Appliqu\u00e9e \u00e0 la Dermatologie, H\u00f4pital de l'Archet 2"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "3", 
        "official_title": "Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100", 
        "overall_official": {
            "affiliation": "CPCAD, Centre de Pharmacologie Clinique Appliqu\u00e9e \u00e0 la Dermatologie", 
            "last_name": "Catherine Queille-Roussel, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Mean Cumulative Irritation index and maximal dermal response during induction phase", 
                "safety_issue": "Yes", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "Number of subjects with positive sensitisation reaction at each test site in the challenge phase", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01935869"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "LEO Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LEO Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}